Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bowel Preparation for Inpatient Colonoscopy

This study has been completed.
Information provided by:
Santa Clara Valley Health & Hospital System Identifier:
First received: July 20, 2010
Last updated: October 12, 2016
Last verified: May 2016
This study will compare two strategies for bowel cleansing prior to inpatient colonoscopy: the entire preparation taken the night before the procedure versus half the preparation taken the night before the procedure, and the other half taken the morning of the procedure.

Condition Intervention Phase
Gastrointestinal Hemorrhage
Colon Cancer
Drug: Go-Lytely
Drug: Go Lytely
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
Primary Purpose: Diagnostic
Official Title: Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy

Resource links provided by NLM:

Further study details as provided by Santa Clara Valley Health & Hospital System:

Primary Outcome Measures:
  • Quality of colon cleansing [ Time Frame: 24 hours from study enrollment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient satisfaction [ Time Frame: 24 hours from study enrollment ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: July 2010
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Split prep Drug: Go Lytely
Bowel cleansing agent
Active Comparator: Whole prep Drug: Go-Lytely
Bowel cleansing agent


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • any diagnosis for which colonoscopy is indicated

Exclusion Criteria:

  • ileus
  • severe colitis/toxic megacolon
  • gastric retention
  • bowel perforation
  • gastrointestinal obstruction
  • gastroparesis that precludes oral bowel preparation
  • pregnant or lactating women
  • allergy to polyethylene glycol.
  • unable to give consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01169220

United States, California
Santa Clara Valley Medical Center
San Jose, California, United States, 95128
Sponsors and Collaborators
Santa Clara Valley Health & Hospital System
  More Information

Responsible Party: Ahmad Kamal, Santa Clara Valley Medical Center Identifier: NCT01169220     History of Changes
Other Study ID Numbers: 10-041 
Study First Received: July 20, 2010
Last Updated: October 12, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Santa Clara Valley Health & Hospital System:
Bowel preparation

Additional relevant MeSH terms:
Gastrointestinal Hemorrhage
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases
Pathological Conditions, Anatomical processed this record on October 21, 2016